share_log

Zacks Small Cap Weighs in on ABVC BioPharma, Inc.'s Q1 2023 Earnings (OTCMKTS:ABVC)

Financial News Live ·  Jan 21, 2023 02:41

ABVC BioPharma, Inc. (OTCMKTS:ABVC – Get Rating) – Zacks Small Cap issued their Q1 2023 EPS estimates for ABVC BioPharma in a report issued on Wednesday, January 18th. Zacks Small Cap analyst M. Marin anticipates that the company will post earnings per share of ($0.05) for the quarter. The consensus estimate for ABVC BioPharma's current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for ABVC BioPharma's Q2 2023 earnings at ($0.06) EPS, Q3 2023 earnings at ($0.05) EPS and Q4 2023 earnings at ($0.04) EPS.

Get ABVC BioPharma alerts:

Separately, Maxim Group downgraded shares of ABVC BioPharma from a "buy" rating to a "hold" rating in a research note on Wednesday, November 16th.

ABVC BioPharma Stock Performance

Shares of ABVC stock opened at $0.78 on Thursday. The company's fifty day simple moving average is $0.75 and its 200-day simple moving average is $0.79. ABVC BioPharma has a 52 week low of $0.50 and a 52 week high of $3.13. The company has a market cap of $25.45 million, a PE ratio of -1.15 and a beta of 0.50.

ABVC BioPharma (OTCMKTS:ABVC – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.09. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.03 million.

About ABVC BioPharma

(Get Rating)

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.

See Also

  • Get a free copy of the StockNews.com research report on ABVC BioPharma (ABVC)
  • MarketBeat Week in Review – 1/16 – 1/20
  • Does Old Dominion Show That Trucking Is Hitting The Brakes?
  • Nordstrom Puts Fear Of Markdowns Into Retail Sector
  • Exxon Mobil Stock: Within Striking Distance Of Buy Point
  • High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment